Evaluate w H P including contributing meds risk factors and perform stone analysis urine blood biochemistry in all first time stone formers for potential treatable metabolic d o tailored tx 1 2 Ca stones are most common type 3 Perform detailed eval in hig

By vgreene, 10 July, 2024
Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> <b>AUA 2014</b> [S/B]. Pearle M, et al. Medical management of kidney stones: AUA Guideline. <a href=https://www.auajournals.org/doi/epdf/10.1016/j.juro.2014.05.006><b>PDF</b></a>
<br><br>
<sup>2</sup> <b>EAU 2024.</b> Skolarikos A, et al. EAU Guidelines on Urolithiasis. European Association of Urology. <a href=https://uroweb.org/guidelines/urolithiasis/chapter/guidelines><b>Online</b></a> <a href=https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urolithiasis-2024.pdf><b>PDF</b></a>
<br><br>
<sup>3</sup> <b>ACP 2014</b> [WR/L]. Qaseem A, et al. Dietary and Pharmacologic Management to Prevent Recurrent Nephrolithiasis in Adults: A Clinical Practice Guideline From the American College of Physicians. <i>Ann Intern Med</i>. 2014. Nov 4;161(9):659-667. <a href=https://www.acpjournals.org/doi/full/10.7326/M13-2908><b>Accessed 6/24/24</b></a>
Detail Type
Text
Patient Type Detail Header (Long)
Evaluate w/ H&P, including contributing meds & risk factors and perform stone analysis ± urine/blood biochemistry in all first-time stone formers for potential, treatable metabolic d/o & tailored tx.<sup>1,2</sup> Ca++ stones are most common type.<sup>3</sup> Perform detailed eval in high risk/recurrent stone-formers only [B], per AUA.<sup>1</sup> ACP says evidence insufficient that stone composition and blood/urine monitoring reduce recurrence<sup>3</sup>